| Literature DB >> 32581644 |
Vidhya Natarajan1, Preeti Moar1, Urvinder S Kaur1, Vimala Venkatesh1, Abhishek Kumar1, Rupesh Chaturvedi1, D Himanshu1, Ravi Tandon1.
Abstract
BACKGROUND: Helicobacter pylori are gram-negative bacteria, which colonize the human stomach. More than 50% of the world's population is infected by H. pylori. Based on the high prevalence of H. pylori, it is very likely that HIV and H. pylori infection may coexist. However, the molecular events that occur during HIV-H. pylori co-infection remain unclear. Latent HIV reservoirs are the major obstacle in HIV cure despite effective therapy. Here, we explored the effect of H. pylori stimulation on latently HIV-infected monocytic cell line U1.Entities:
Keywords: ART; HIV; Helicobacter pylori; LRA; gene expression; infected monocytes
Year: 2019 PMID: 32581644 PMCID: PMC7290055 DOI: 10.2174/1389202921666191226091138
Source DB: PubMed Journal: Curr Genomics ISSN: 1389-2029 Impact factor: 2.236
Number of differentially expressed genes (DEGs) and differentially regulated KEGG pathways among in H. pylori-HIV co-infected cells compared to the control. The DEGs included had p<0.05 and Fold change >2. The KEGG pathways were enriched using KOBAS 3.0. The HH represents HIV-H. pylori co-infected U1 cells and H represents U1 cells with latent HIV only.
|
|
|
|
|---|---|---|
| DEGs | Up-regulated | 197 |
| Down-regulated | 101 | |
| Total | 298 | |
| KEGG pathways | Up-regulated | 152 |
| Down-regulated | 104 | |
| Total | 256 |
Enrichment of GO biological process categories. The enriched genes were significantly overrepresented in the list of DEGs in H. pylori co-infected HIV cells compared to the control (p<0.05 and FDR<0.05). GO biological process were analysed using panther version 14.0.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Granulocyte chemotaxis | GO:0071621 | 5.94 | 2.15E-05 | 2.96E-03 | CXCL6, CXCL8, CCL2, CXCL3, IL1B, CCL26, CCL3, CCL20, CCL1, CXCL2 |
| Cellular response to lipopolysaccharide | GO:0071222 | 5.73 | 4.51E-04 | 3.23E-02 | CXCL6, CXCL8, CXCL3, CD14, IL1B, CD86, CXCL2 |
| Positive regulation of NF-kappaB transcription factor activity | GO:0051092 | 4.85 | 4.88E-04 | 3.35E-02 | CD14, NFKB2, TLR7, RELB, IL1B, TNFRSF19, IRAK2, NLRC4 |
| Cell chemotaxis | GO:0060326 | 4.83 | 1.99E-06 | 5.94E-04 | CXCL6, CXCL8, CCL2, CXCL3, CCRL2, CCR1, VEGFA, IL1B, CCL26, CCL3, CXCR3, CCR2, CCL20, CCL1, CXCL2 |
| Cytokine-mediated signaling pathway | GO:0019221 | 3.4 | 4.32E-04 | 3.22E-02 | CXCL6, CXCL8, CCL2, CXCL3, F3, IL1B, CCL26, CCL3, IRAK2, CCL20, CCL1, CXCL2 |
Pathway analysis using significantly up-regulated (p<0.05 and FC>2) differentially expressed genes. The KEGG pathways were analysed using KOBAS version 3.0. with P<0.05 and FDR<0.05 using Fisher’s exact test. The top 10 pathways are listed based on p value.
|
|
|
|
|
|
|---|---|---|---|---|
| Pathways in cancer | hsa05200 | 13 | 0.00038 | 0.005805 |
| NF-kappa B signaling pathway | hsa04064 | 10 | 7.76E-08 | 1.18E-05 |
| Metabolic pathways | hsa01100 | 10 | 0.821779 | 0.843989 |
| TNF signaling pathway | hsa04668 | 9 | 2.03E-06 | 0.000121 |
| Rheumatoid arthritis | hsa05323 | 8 | 9.35E-06 | 0.000355 |
| Osteoclast differentiation | hsa04380 | 8 | 5.78E-05 | 0.001756 |
| Apoptosis | hsa04210 | 8 | 0.000131 | 0.002926 |
| Influenza A | hsa05164 | 8 | 0.000545 | 0.005805 |
| Transcriptional misregulation in cancer | hsa05202 | 8 | 0.000573 | 0.005805 |
| Herpes simplex infection | hsa05168 | 8 | 0.000761 | 0.007231 |
Pathway analysis using significantly down-regulated (p<0.05 and FC>-2) differentially expressed genes. The KEGG pathways were analysed using KOBAS version 3.0. with P<0.05 and FDR<0.05 using Fisher’s exact test. The top 10 pathways are listed based on p value.
|
|
|
|
|
|
|---|---|---|---|---|
| Metabolic pathways | hsa01100 | 8 | 0.30158 | 0.49478 |
| PI3K-Akt signaling pathway | hsa04151 | 5 | 0.033428 | 0.447981 |
| Hippo signaling pathway | hsa04390 | 4 | 0.007728 | 0.344734 |
| Complement and coagulation cascades | hsa04610 | 3 | 0.006738 | 0.344734 |
| Bacterial invasion of epithelial cells | hsa05100 | 3 | 0.009944 | 0.344734 |
|
|
|
|
|
|
| Amoebiasis | hsa05146 | 3 | 0.018338 | 0.447981 |
| Transcriptional misregulation in cancer | hsa05202 | 3 | 0.063433 | 0.468753 |
| Epstein-Barr virus infection | hsa05169 | 3 | 0.095542 | 0.468753 |
| Focal adhesion | hsa04510 | 3 | 0.101789 | 0.468753 |
| MAPK signaling pathway | hsa04010 | 3 | 0.142424 | 0.469822 |